Updated:
Mendaera
Mendaera was founded to address the steep learning curve that constrains ultrasound-guided needle procedures.
Mendaera
Mendaera was founded to address the steep learning curve that constrains ultrasound-guided needle procedures. The firm's core innovation is a handheld robotic platform that pairs real-time imaging with automated needle guidance, allowing a broader range of clinicians to perform interventions that currently require years of specialized training. Investors backing the company include institutional venture firms that target medical-device and health-technology categories, though the firm does not publicly disclose its ownership structure or individual backers beyond a roster of institutional logos on its website. The Focalist system targets needle-based procedures such as biopsies and vascular access, operating at the intersection of medical robotics, digital-health data infrastructure, and interventional hardware. Mendaera's regulatory strategy reached an inflection point when it received FDA clearance for the Focalist platform, transitioning the firm from preclinical development into commercial deployment. The company subsequently announced completion of the world's first procedures using the system, demonstrating clinical use in live patient settings. Mendaera does not reveal specific hospital partners or case volumes, and its geographic footprint appears concentrated in the United States during this early commercialization phase. Mendaera operates from its headquarters in San Mateo, California, and maintains a lean public profile consistent with an early-stage medical-device company. The firm has not disclosed team size, additional office locations, or adjacent vehicles such as a philanthropic foundation. Its website suggests ongoing customer expansion and invites prospective users to register for updates and demonstrations, indicating an active sales cycle. The company's most recent verifiable operational milestone is the FDA clearance of the Focalist platform and the subsequent first-in-human procedures, both announced on its website with an implied date in 2025 or 2026. What structurally distinguishes Mendaera is its product architecture rather than its corporate form: the Focalist system compresses a robotic-guidance capability into a handheld form factor intended for use by non-specialist clinicians, a design choice that positions the technology closer to a consumable tool than to a capital-equipment robotic tower. Unlike large surgical-robotics platforms that require dedicated operating-room infrastructure and prolonged installation, Focalist aims to operate within existing clinical workflows. This portability creates a different commercial adoption path — one that competes against training-intensive manual techniques rather than against other capital-intensive robotic systems.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Mateo
Corporate office
San Mateo, CA, United States
Sector focus
Frequently asked questions
What does Mendaera's Focalist system actually do?
Focalist combines a handheld robotic device with real-time ultrasound imaging to guide needle placement during procedures such as biopsies and vascular access. The system aims to automate the precision component that normally requires years of clinician training, making image-guided interventions reproducible by a broader range of healthcare providers. It received FDA clearance and has been used in live clinical procedures, per the company.
How does Mendaera's technology differ from established surgical-robotics platforms?
Rather than a multi-arm console anchored in a dedicated operating room, Focalist is a handheld instrument designed for portability and point-of-care use. The architecture targets the manual dexterity challenge of needle guidance — not large-incision surgery — and is intended to integrate into existing clinical workflows without requiring capital-intensive infrastructure. Its adoption path competes against the training bottleneck in ultrasound-guided procedures rather than against other robotics capital-equipment purchases.
What regulatory milestones has Mendaera achieved?
Mendaera announced FDA clearance for the Focalist platform, marking the shift from development to commercial use in the United States. The company subsequently reported the world's first procedures performed with the system, establishing clinical-use evidence in live patient settings. No other geographic regulatory approvals have been disclosed publicly.
Who has invested in Mendaera?
The firm's website displays logos of institutional investors described as 'Investors that power progress,' but Mendaera does not name individual backers, disclose funding round details, or publish capitalization figures. No public regulatory filings revealing the capital structure are currently available, leaving the investor syndicate unconfirmed.
Is Mendaera currently available for commercial purchase?
The company's website invites healthcare providers and potential customers to sign up for updates, exclusive demos, and early opportunities, suggesting an active but early-stage commercial rollout. Mendaera also directs existing customers to contact support for Instructions for Use documentation, indicating that some units are already in clinical use. Pricing and distribution models have not been publicly disclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: